
Sign up to save your podcasts
Or
As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.
4.8
1313 ratings
As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.
164 Listeners
1,080 Listeners
339 Listeners
206 Listeners
165 Listeners
186 Listeners
341 Listeners
220 Listeners
266 Listeners
189 Listeners
209 Listeners
551 Listeners
78 Listeners
164 Listeners
485 Listeners